Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy.Taking a blood sample – illustrative photo. Image credit: Annett Klingner via Pixabay, free license In the ever-evolving battle against cancer, immunotherapy presents a turning point. It began with harnessing the body’s...
